We are dedicated to developing therapies to treat, slow, or prevent disease progression and improve the quality of life for patients with obesity, type 2 diabetes mellitus (T2DM), and cardiovascular (CV) and kidney diseases.
For more than 50 years, Pfizer has led the way in redefining the management of cardiovascular risk by bringing much-needed treatments to patients.
Today, Pfizer is focused on investigating potential therapies that treat both the metabolic abnormalities that increase the likelihood of cardiovascular diseases and the heart itself by trying to alter the way it responds to the abnormal metabolic state. This includes more targeted potential therapies, as well as possible therapies that are a combination of two or more drugs, which could bring additional benefits to patients.
Our early discovery efforts focus on emerging areas of CV research such as control of eating disorders, type 2 diabetes mellitus/muscle uptake of glucose and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH).